We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3040 95 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Regeneron (REGN) is a biotech working in recombinant DNA technology. Until '94 it generally traded between 10 and 20 dollars until the FDA beat it up on it's treatment for Lou Gehrig's Disease. While it was trading at the $4 level at the end of '94, the former chairman of Merck(I believe) took the helm and the stock climbed back to about 11, then traded between 11 and 14. In late May, Option volume increased, news about a discovery concerning muscles was announced, and the stock has risen sharply to Friday, May 24 '96 close of 18.875.

Historically, the stock has failed around 22. Yet AMGEN has more than a 17.7% stake with warrants to increase it's stake to 20%, at 16$ per share. Could this be the time it breaks out?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3040IL6 level is lower than in active RA, and sIL6R level (actual target in COVID) iMiljenko Zuanic-yesterday
3039Is a “Cytokine Storm” Relevant to COVID-19? "...Several earnigel bates-yesterday
3038That's ok. I appreciate the message. All is forgiven. I think these smallCuttingEdge Bio-yesterday
3037What does the phrase, “strict-term” mean?DewDiligence_on_SI-Thursday Smart trial setup for phase 3 - prevention. Biotechwantabe-Thursday
3035I have to apologize here, and I am apologizing! Kevzara did not show efficacy inMiljenko Zuanic-Thursday
3034They had They time to prepare NY manufacturing facility, for covid. For Dupi anMiljenko Zuanic-Wednesday
3033If other parties are involved in order to meet worldwide demand for a successfulCuttingEdge Bio-Tuesday
3032All I want is to be rational with COVID. World needs good-effective treatment oMiljenko Zuanic-Tuesday
3031Everything I read gives me a bit of confidence that regeneron would have best mABiotechwantabe-Monday
3030From before we know that BARDA/NIH is sponsoring/collaborating on Kevzara P2/3 tMiljenko Zuanic-Monday
3029Regeneron Pharmaceuticals, Inc USAProduct Name: SarilumabDescription: Kevzara (Biotechwantabe-Monday
3028Thanks for sharing although I don't think it's known but there must be sFelix B-Monday
3027BARDA financing is (so far), $82M for R&D and $85M for P1/2: meMiljenko Zuanic-Monday
3026I don't think REGN can price any treatment right, either upset public or walFelix B-Monday
3025Remd at $2-3K per treatman (with very limited benefit) is prised exceptionally wMiljenko Zuanic-Monday EGFR and Squamous Cell Carcinoma of the Lungs The EGFR pathwBiotechwantabe1last Saturday
3023R.I.P ABBV's Abicipar (DARPin) for wet AMD: investorshub.advfn.comDewDiligence_on_SI1June 26
3022Regeneron plans to begin a clinical trial with EGFRxCD28 (REGN7075) and Libtayo Biotechwantabe1June 25
3021Adjuvant/neoadjuvant sSCC is much bigger market.Miljenko Zuanic-June 25
3020FDA approves Keytruda monotherapy in cSCC: businesswire.comDewDiligence_on_SI-June 25
3019Will see how much will REGN charge BARDA for 2Q?Miljenko Zuanic-June 25
3018Wow, unexpected and I am am not sure how to interpret this...?Felix B-June 24
3017Pretty sure BARDA funded R&D just as they did for Ebola and that's why IFelix B-June 24 24
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):